A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis
- Multiple Sclerosis
- **other criteria will apply
For more information, call Allison Emborsky at 716-558-3543 or email email@example.com. You can also visit:
Want to participate in a study?
Fill out the form below and one of our Research Coordinators will be in contact with you as soon as possible. If we currently do not have a study that is currently available for you, we will add you to our database for future studies.